Search
Deciphera Pharmaceuticals, Inc.
  • About Us
    • Overview
    • Management
    • Board of Directors
    • Advisors
    • Funding and Support
    • Compliance
  • Our Pipeline
    • Overview
    • Our Medicine
    • Ripretinib (DCC-2618)
    • Rebastinib
    • DCC-3014
    • Expanded Access
  • Our Focus on Patients
    • Our Focus on Patients and Families
    • Gastrointestinal Stromal Tumors (GIST)
    • Breast Cancer
    • Tenosynovial Giant Cell Tumors (TGCT)
  • Our Research
    • Kinases in Cancer
    • Our Kinase Switch Control Platform
    • Presentations and Publications
  • Our Workplace
    • Our Culture and Values
    • Join Our Team
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Press Releases
    • Deciphera in the News
    • Events and Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • FAQs
      • Contact IR
      • Email Alerts
  • Contact

Deciphera in the News
»
  • Stock Information
    • Stock Quote & Chart
  • Press Releases
  • Deciphera in the News
  • Events and Presentations
  • Financial Information
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
  • Investor Resources
    • FAQs
    • Contact IR

  • 2021
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014
Jan
11
2019

FierceBiotech

Deciphera CBO Morl talks lines of therapy for kinase inhibitor ripretinib

Jun
08
2017

The Inaugural Einstein-Montefiore Presidential Lecture: Dr. John Condeelis (Full Lecture)

Introduction to the Problem

How can we inhibit TMEM function?

Jan
24
2017

EP Vantage

Vantage point – Life for kinase inhibitors in an immuno-oncology world

Dec
05
2016

EBD Group

BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance

Apr
25
2016

BioWorld Insight, April 25, 2016. Volume 24, No. 17

T cells are immunotherapy stars, but in an ensemble performance

Sep
22
2015

BioWorld Today- September 22, 2015

Deciphera advancing oncology pipeline with $75M series B round

Nov
17
2014

OncLive

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

Nov
17
2014

Boston Business Journal

Deciphera Says Cancer Drug May Work Against Brain Cancer

Apr
07
2014

Fierce Biotech

Little Deciphera Raises its Cancer R&D Flag in Boston's Bustling Biotech Hub

© 2021 Deciphera Pharmaceuticals, Inc. Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • About Us
    • Overview
    • Management
    • Board of Directors
    • Advisors
    • Funding and Support
    • Compliance
  • Our Pipeline
    • Overview
    • Our Medicine
    • Ripretinib (DCC-2618)
    • Rebastinib
    • DCC-3014
    • Expanded Access
  • Our Focus on Patients
    • Our Focus on Patients and Families
    • Gastrointestinal Stromal Tumors (GIST)
    • Breast Cancer
    • Tenosynovial Giant Cell Tumors (TGCT)
  • Our Research
    • Kinases in Cancer
    • Our Kinase Switch Control Platform
    • Presentations and Publications
  • Our Workplace
    • Our Culture and Values
    • Join Our Team
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Press Releases
    • Deciphera in the News
    • Events and Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • FAQs
      • Contact IR
      • Email Alerts
  • Contact